We are live on
!
Find out more
Allogene Therapeutics
ALLO
ALLO
208 hedge funds and large institutions have $445M invested in Allogene Therapeutics in 2026 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 80 increasing their positions, 40 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
317% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 12
108% more call options, than puts
Call options by funds: $776K | Put options by funds: $373K
100% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 40
100% more capital invested
Capital invested by funds: $223M → $445M (+$222M)
21% more funds holding
Funds holding: 172 → 208 (+36)
3.16% more ownership
Funds ownership: 72.38% → 75.54% (+3.2%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Holders
208
Holders Change
+36
Holders Change %
+20.93%
% of All Funds
2.56%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
50
Increased
80
Reduced
40
Closed
12
Calls
$776K
Puts
$373K
Net Calls
+$403K
Net Calls Change
+$167K
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$11.8M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$6.34M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
+$5.46M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$4.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.35M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$10.7M |
| 2 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
-$3.49M |
| 3 |
Jane Street
New York
|
-$3.32M |
| 4 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$3.03M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.82M |
